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newly diagnosed FLT3-mutated AML patient 60 years was estimated at $114,193
compared to $105,819 for patients with non-FLT3-mutated AML. As early mortality
and early retirement were not included in indirect costs, these may be
underestimated. CONCLUSIONS: FLT3-mutated AML potentially represents a
greater per-patient burden than non-FLT3-mutated AML due to shorter survival
and greater use of stem cell transplants. Investigational treatments targeting the
FLT3 mutation may provide an additional therapeutic option and have the poten-
tial to improve clinical outcomes.
PSY20
COSTS ASSOCIATED WITH THE BURDEN OF JOINT PAIN IN HEMOPHILIA A AND
B PATIENTS WITH AND WITHOUT INHIBITORS
Cyaniuk A1, Smith C2, Upadhyay A1, Swallow E1, Cooper D2, Wisniewski T2
1OptumInsight, Horsham, PA, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA
OBJECTIVES: Hemophilia patients frequently experience joint bleeding, resulting
in persistent pain and arthropathy. The objective of this study was to determine
drivers of total and hemophilia-related costs among hemophilia patientswith joint
pain.METHODS: InVision™ Data Mart (OptumInsight Life Sciences, 1/2005-3/2009)
was used to identify male patients with hemophilia A/B (ICD-09 286.0 and 286.1)
who were treated with FVIII/FIX/bypassing agent and had  2 years of continuous
enrollment from index. Patients were stratified into severe joint pain (SJP), 2 joint
pain claims (ICD-9 713, 715, 716, 718, 719, 727) 12 months pre or 6 months post
index, andminimal joint pain (MJP), 2 pain claims. Cohorts werematched on age,
treatment type and Charlson comorbidity scores via propensity scoring. Random
forest analysis informed covariate selection for log-transformed linear regression
models. Covariate selection was further refined based on variance inflation, vari-
able significance and medical relevance. RESULTS: A total of 284 patients (142 SJP,
142 MJP); mean age30 years were identified. Mean (median) total cost of all pa-
tients was $630K ($248K) over a 2-year period but were significantly higher for SJP-
$917K compared to MJP- $354K (p0.01). Hemophilia therapy was the main driver
of total patient cost (p0.0001). Home health visits (p0.0001), hemophilia-related
hospital visits (p0.0001) and age (p0.01) were also significant drivers of SJP costs.
Removal of covariates measuring factor therapy or claims with hemophilia diag-
noses showed that joint pain claims (p0.01), injectible medications (p0.01),
Charlson Comorbidity Index (p0.01), non-hemophilia lab tests (p0.01), anti-in-
fective medications (p0.01), and age (p0.001) were significantly related to total
patient cost.CONCLUSIONS:The treatment of joint painmarks significantly higher
hemophilia costs, however, some of these differences may be attributed to hemo-
philia severity (not coded within ICD-9). Modification of ICD-9 codes may help
understand economics among hemophilia patients in the future.
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OBJECTIVES: Postherpetic neuralgia (PHN) is a painful, chronic condition. Gabap-
entin and pregabalin are common first-line medications for PHN and must be
titrated over time to effective doses. Individuals with PHN may augment therapy
with opioids to control pain. Pain management for PHN can require substantial
healthcare resources. The study objective was to evaluate costs for persons with
PHN. METHODS: This retrospective claims database analysis used medical and
pharmacy claims data and enrollment information for adult commercial andMedi-
care Advantage enrollees in a large, national US health plan. Patients had1 phar-
macy claim for gabapentin or pregabalin from January 2006–February 2009; the
date of the first claimwas the index date. Patients also had diagnosis codes for PHN
(ICD-9-CM 053.1x) on or within 2 days after the index date; and 6-month and 12-
month pre- and post-index periods, respectively, during which they were contin-
uously enrolled. Total medical, outpatient pharmacy, and health care (medical 
pharmacy) post-index costs per patient with PHN per month were compared be-
tween gabapentin and pregabalin cohorts. RESULTS: The study population com-
prised 1645 patients, 939 in the gabapentin cohort and 706 in the pregabalin cohort;
77.6% were commercial enrollees and 22.4% were Medicare Advantage enrollees.
The mean (standard deviation) monthly healthcare costs were $1,749 ($6,117) for
the gabapentin cohort and $1,570 ($4,935) for the pregabalin cohort (p0.512).Mean
monthly medical costs were $1326 ($5831) in the gabapentin cohort and $985
($4,753) in the pregabalin cohort (p0.192). The pregabalin cohort had highermean
monthly pharmacy costs ($585 [$727]) than did the gabapentin cohort ($423 [$755],
p0.001). CONCLUSIONS: Health care costs for patients with PHN are substantial:
approximately $1700 per person with PHN per month, and approximately $20,000
per year. Health care costs between the gabapentin and pregabalin cohorts were
not significantly different despite significantly different mean pharmacy costs.
PSY22
HEALTH CARE COSTS FOR INFLAMMATORY BOWEL DISEASE PATIENTS WHO
ARE ADHERENT VERSUS NON-ADHERENT WITH INFLIXIMAB THERAPY
Wan G1, Kozma C2, Slaton T3, Olson W4, Feagan B5
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Independent Research Consultant/Adjunct
Professor, University of South Carolina, St. Helena Island, SC, USA, 3Independent Consultant,
West Columbia, SC, USA, 4Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 5Robarts Research
Institute The University of Western Ontario, London, ON, Canada
OBJECTIVES: Prior research evaluated the impact of infliximab (IFX) adherence on
resource use and costs in Crohn’s disease (CD). Purpose was to examine the asso-
ciation between adherence and all-cause healthcare costs among those who are
treatedwith IFX for inflammatory bowel disease (IBD).METHODS: Patients with1
claims for IFX initiated between January 1, 2006 to December 31, 2009 who had 2
IBD diagnoses of Crohn’s disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC;
ICD-9-CM: 556.XX) during the pre-index period were identified from Thomson Reu-
ters Marketscan® Databases. Patients had to be 18 years, continuously enrolled for
12 months before and after IFX initiation, and had no prior use of IFX during 360-
days pre-index. Patients with prior biologic therapy or rheumatoid arthritis (ICD-
9-CM: 714.XX) were excluded. Adherent group was classified as having a medica-
tion possession ratio (MPR) of 80%; non-adherent group had an MPR80%.
Differences between the adherent and non-adherent groups were assessed using
propensity-weighted general linear models. RESULTS: A total of 1,646 IBD patients
were identified (945 CD; 701 UC) with a mean (SD) age of 44.4 (15.6) and 48.3% were
female. Of these, 41% were adherent and 59% were non-adherent. Propensity-
weighted mean total healthcare costs excluding IFX were $13,424 vs. $32,522
(P0.0001) for the adherent vs. non-adherent groups. Mean all-cause component
costs were $2,458 vs. $17,634 (P0.0001) for hospitalizations, $7,357 vs. $10,909
(P0.0001) for outpatient visits, and $236 vs. $458 (P0.0001) for ER visits in the
adherent vs. non-adherent groups, respectively; total costs (component IFX)were
also significantly lower in the adherent group. No significant differences were ob-
served in other prescription costs. CONCLUSIONS: Medication adherence was as-
sociated with significantly lower total healthcare costs in patients treated with IFX
for IBD. These differencesmay be explained by reducedhospitalization, outpatient,
and ER costs observed in the adherent vs. non-adherent groups.
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OBJECTIVES: Little data are available on the burden of ASM, a subtype of systemic
mastocytosis (SM) and severe form of mast cell disease that may progress to mast
cell leukemia. This study reviewed the literature in order to estimate the burden of
ASM in theUS.METHODS:Asystematic literature reviewwas conducted to identify
publications from2000-2011; 181 citationswere identified and 6 articles abstracted.
TheUS population-level burden of ASMwas estimated using an Excelmodel. Direct
treatment costs were calculated from treatment patterns described in identified
publications. RESULTS: ASM involves multiple organ systems, resulting in poten-
tially severe symptoms/conditions including anaphylaxis/allergic reactions, osteo-
porosis, hepatomegaly, splenomegaly, gastrointestinal symptoms, fatigue, and
weight loss. There is no known cure for ASM. Median survival was 41 months in a
published cohort study. No publicationswere identified providingUS epidemiology
data. Two estimates were calculated for the prevalence of ASM in the US in 2010:
616 and 1,220. A global prevalence rate of 0.2/100,000 resulted in 616 cases. An SM
prevalence rate of 3.3/100,000 (assuming 12% ASM) resulted in 1,220 cases. Inci-
dence was estimated at 111 cases in 2010 using an SM incidence rate of 0.3/100,000
(assuming 12% ASM). The proportion of ASM/SM cases ranged from 7-18% in the
literature with 12% from the largest study. No studies were identified examining
the economic burden of ASM. In this model, direct monthly per-patient costs were
estimated between $5232 and $8741. These are likely underestimated as a result of
limited resource utilization information in the literature. CONCLUSIONS: These
results provide preliminary estimates for the burden of ASM in the UNITED
STATES. Additional research can assist in further quantifying these estimates. In
addition, it is likely that ASM patients experience tremendous indirect costs due to
the symptomatic burden of the disease and further evaluation is warranted.
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OBJECTIVES: To evaluate the association of patient cost or reimbursement chal-
lenges with healthcare resource utilization, quality of life (QoL), and work produc-
tivity among patients with inflammatory bowel disease (IBD).METHODS: A syndi-
cated study of IBD patients in the USwas conducted. Patients18 years of agewere
recruited via the National Health and Wellness Survey and Lightspeed Research
Panel. Patients completed a survey during August–November 2010 in which they
were asked if they experienced cost or reimbursement challenges related to pre-
scription medication. The Medical Outcomes Study (MOS) IBD questionnaire was
used to assess QoL. Work productivity was assessed using the Work Productivity
and Activity Impairment (WPAI) questionnaire. To measure health care resource
utilization, the number of provider, emergency room (ER) and hospital visits in the
past six months was collected. Bivariate differences between the patient groups
(those with cost or reimbursement issues versus those without) for resource utili-
zation, QoL, and work impairment were assessed using chi-square tests for cate-
gorical variables and t-tests for continuous variables. RESULTS: Of 1098 IBD pa-
tients currently receiving prescription medication, 21% (n231) reported that cost
had previously prevented them from taking medication. Among patients who had
ever taken prescription medication (n1343), 13% (n178) reported ever having a
problem getting reimbursed for medication. Sixty-eight of these patients (38%)
indicated theirmedicationwas not covered by insurance. Patients reporting cost or
reimbursement issues had a higher probability of having provider, ER and hospital
visits in the prior six months (all p0.05). Furthermore, these patients reported
greater work impairment and lower QoL (both p0.05). CONCLUSIONS:Among IBD
patients, cost or reimbursement challenges may be associated with more resource
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